Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA) to include patients with FGFR2 gene mutations or amplifications

NEXT STORY
Novartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies
PREV STORY
ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Press Release Oncology Venture will offer new shares in exchange for previously annulled warrants as part of clean-up of remaining obligations incurred prior to former management departure

author_avatar
NASDAQ Market News

Arizona Community Physicians Modernizes Infrastructure, Speeds Applications to Improve Patient Care with NetApp

SUNNYVALE, Calif., March 27, 2018 (GLOBE NEWSWIRE) -- NetApp (NASDAQ:NTAP), empowering its customers to ...

author_avatar
NASDAQ Market News

Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency

author_avatar
NASDAQ Market News